Document is current

Any future updates will be listed below

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Crossref DOI link: https://doi.org/10.1186/s13052-017-0390-8

Published Online: 2017-08-14

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark